Introduction {#Sec1}
============

Millions of people worldwide are exposed to arsenic in drinking water (Ravenscroft et al. [@CR47]), an established cause of lung cancer (IARC [@CR27]). Arsenic affects many body tissues, but the human lung seems particularly susceptible (NRC [@CR39]). In fact, lung cancer appears to be the most common cause of death from arsenic in drinking water (Smith et al. [@CR48]; Yuan et al. [@CR59]). Most lung carcinogens---including tobacco smoke, asbestos, and silica---also cause non-malignant respiratory effects. The first evidence that ingested arsenic might follow this pattern came from the limited investigations of children in Antofagasta, Chile (Borgoño et al. [@CR6]; Zaldivar [@CR60]). More recently, studies have linked arsenic in drinking water to lung function, cough, breathlessness, crepitations, chronic bronchitis, and bronchiectasis (De et al. [@CR12]; Guha Mazumder et al. [@CR19], [@CR20]; Guo et al. [@CR21]; Milton and Rahman [@CR35]; Parvez et al. [@CR40]; von Ehrenstein et al. [@CR55]). Most data, however, involve adults with recent exposures. The long-term impacts of early-life arsenic exposures are largely unknown. An ecologic study of northern Chile found increased lung cancer, bronchiectasis, and other chronic obstructive pulmonary disease (COPD) mortality several decades after high in utero and early-childhood arsenic exposure (Smith et al. [@CR49])*.* In this paper, we present a pilot study on adult lung function in relation to estimated early-life exposure in the same region using individual-level data.

Materials and methods {#Sec2}
=====================

Study area {#Sec3}
----------

Northern Chile is among the driest places on Earth. Nearly everyone there obtains water from municipal supplies, which have arsenic measurements dating back to the 1950s. The absence of alternative water sources means that people's lifetime arsenic exposures can be estimated simply by knowing in which cities they lived. In Antofagasta (population 257,976), drinking water arsenic concentrations were about 90 μg/l until 1958, when arsenic-contaminated rivers were tapped to supply the growing population. Drinking water concentrations averaged 870 μg/l until the world's first large arsenic removal plant became operational in May 1970. From then on, concentrations remained below 150 μg/l with few exceptions. Current levels are around 10 μg/l, the World Health Organization guideline (WHO [@CR58]). This unusual exposure scenario created a population of tens of thousands of people exposed to high levels of arsenic in utero or as young children but not as adults. By contrast, the nearby city of Arica (population 193,788) has always had drinking water arsenic levels around 10 μg/l. Other cities in northern Chile had variable arsenic levels, but none approached those of Antofagasta (Ferreccio et al. [@CR16]).

Study design and participants {#Sec4}
-----------------------------

In this pilot study, we compared lung function and prevalence of respiratory symptoms in adults with and without high early-life arsenic exposures. The exposed population comprised long-term residents of Antofagasta, while the unexposed comparison group comprised mostly long-term residents of Arica. A convenience sample was recruited by 2 local nurse-interviewers in each city, who invited employees at the major nursing schools (Universidad Tarapacá de Arica and Universidad de Antofagasta) through personal communication and fliers posted on campus. Interviews and lung function tests were conducted from August 11--21, 2008, in a classroom on campus for 3 days in each city. In total, we enrolled 97 subjects, primarily administrative staff, custodians, and facility workers. Participants were 32--65 years old, such that they would have been young children or in utero during the high exposure period in Antofagasta. The study protocol was approved by the institutional review boards of the University of California, Berkeley, and the Pontificia Universidad Católica de Chile. All subjects gave written informed consent before participating.

Interviews {#Sec5}
----------

Each participant was administered a structured questionnaire to assess lifetime residential and occupational history (all jobs or residences occupied ≥6 months), water source types (municipal tap water, bottled, other), current medications, and medical history. Smoking histories included ages started and quit, years smoked, and average cigarettes smoked per day. Ever smoking regularly was defined as smoking cigarettes at least once per week for ≥1 year, or 20 packs lifetime. Secondhand smoke was defined as someone smoking regularly in the same room at home or at work. Indoor air pollution was defined as irritating or visible smoke, vapors, gases, or dust regularly in the same room. Subjects were also asked about the types of fuels used at home. Occupational exposure was defined as ever being exposed regularly to vapors, dust, gas, or fumes at a job held for ≥6 months (Blanc et al. [@CR4]). Standardized questions were adapted to local Spanish from questionnaires used by the Latin American Project for the Investigation of Obstructive Lung Diseases (PLATINO), the third U.S. National Health and Nutrition Examination Survey (NHANES III), and the second European Community Respiratory Health Survey (ECRHS II).

Questions about respiratory symptoms were adapted from the British Medical Research Council (Cotes [@CR11]). Participants were asked, "Do you often cough when you don't have a cold, such as in the mornings in winter?" Chronic cough was assessed with the follow-up question, "Do you cough like this for at least 3 months a year?" The same questions were asked for phlegm. Subjects were also asked whether they had trouble breathing (1) rarely, (2) often, or (3) always. Finally, participants were asked whether they became breathless when (1) hurrying on level ground or walking up a slight hill, (2) walking with other people of the same age on level ground, or (3) if they had to stop for breath when walking on level ground at one's own pace.

Lung function measurement using spirometry {#Sec6}
------------------------------------------

After height and weight were measured by nurse-interviewers, lung function was assessed according to American Thoracic Society guidelines (ATS [@CR2]) using an EasyOne spirometer (NDD Medical Technologies, Zurich, Switzerland) in diagnostic mode. The same trained technician used the same spirometer in Antofagasta and Arica. Subjects were instructed to take as deep a breath as possible and then blow as hard and long as possible into the spirometer. Following a demonstration and practice with the mouthpiece, they performed tests in a sitting position with active coaching. The main lung function values assessed were forced expiratory volume in 1 s (FEV~1~) and forced vital capacity (FVC). The maneuver was repeated until the EasyOne indicated satisfactory results were achieved (e.g., FEV~1~ and FVC within 200 ml of previous values) or the participant chose to stop. Each subject's best trial (largest sum of FEV~1~ and FVC) was included in analyses. Spirometry data were reviewed by a pulmonologist (JB).

Arsenic exposure assessment {#Sec7}
---------------------------

Municipal drinking water records used in previous studies (Ferreccio et al. [@CR16]; Smith et al. [@CR49]) were linked with each participant's residential history to obtain age-specific estimates of arsenic exposure. The drinking water database included over 15,000 arsenic measurements in Antofagasta and 11 other cities in northern Chile between 1962 and 1990, when concentrations transitioned from high to low. In initial analyses, high exposure in early life was defined as drinking water containing \>800 μg/l arsenic before age 10. The unexposed group included mostly long-term residents of Arica. In our main analyses, the unexposed group also included eight subjects who either moved to Antofagasta (from lower exposure areas) after age 10 or who lived in Antofagasta but were over age 10 during the high exposure period. Sensitivity analyses were conducted to evaluate whether changing cut-offs defining "high exposure" (e.g., 800, 200, or 50 μg/l) and "early-life" (e.g., in utero, 10, or 18 years old) had any impact on results. Exposure--response was assessed both by using early-life arsenic concentration as a continuous variable in models and by stratifying subjects into low, medium, and high exposure categories.

Statistical methods {#Sec8}
-------------------

We analyzed data using SAS 9.2 (SAS Institute Inc., Cary, NC). Student's *t*-tests were used to compare the means of continuous variables. We conducted one-tailed tests of significance for pulmonary outcomes because of the clear direction of a priori hypotheses regarding arsenic. Otherwise, two-tailed tests were used. Lung function mean residuals (observed values *minus* age-, sex-, and height-predicted values) and percentages (observed values *divided by* predicted values) were calculated for subjects with and without high early-life arsenic exposure. Predicted values for northern Chile were not available, so we used those of Mexican Americans in NHANES III (Hankinson et al. [@CR24]). These are within 3% of reference values obtained from the PLATINO study of 5 large Latin American cities (Perez-Padilla et al. [@CR42]). The choice of reference was not critical because our purpose was to compare arsenic exposed and unexposed, for whom the same reference values were used.

Both univariate and multivariate models were performed. We did not enter age, sex, or height in the multivariate models of lung function because "unadjusted" values were residuals and percentages of age-, sex-, and height-predicted values. Final linear models adjusted for ever regularly smoking and variables that were both (1) associated with pulmonary function in other studies and (2) different between the arsenic-exposed and arsenic-unexposed groups in this study (Table [1](#Tab1){ref-type="table"}). These were entered dichotomously: childhood secondhand tobacco smoke (Moshammer et al. [@CR36]); wood, charcoal, or kerosene fuel use in childhood home (Fullerton et al. [@CR17]); occupational air pollution (Blanc et al. [@CR5]); and university graduation, as an indicator of socioeconomic status (Prescott and Vestbo [@CR44]). Adjusted differences between arsenic-exposed and arsenic-unexposed subjects were similar (within 2% predicted FEV~1~) when potential confounders were entered as continuous variables (e.g., cigarettes per day, age started smoking) or multiple indicator variables (e.g., for education: (1) graduating high school, (2) some post-high school, (3) graduating university). Adjusting for outdoor air pollution, adult secondhand smoke, prior diagnosis of respiratory illness including pulmonary tuberculosis, obesity (BMI \> 30 kg/m^2^) at time of interview, number of spirometry maneuvers attempted, or having reproducible spirometry (difference between highest 2 FEV~1~ and FVC values ≤200 ml) likewise had little impact on results. Prevalence odds ratios (PORs) for respiratory symptoms were calculated using the Wald method of logistic regression. Adjusted models included the same variables used for spirometry outcomes, plus age (in years) and sex.Table 1Characteristics of participants \[mean ± SD or *n* (%)\]Peak arsenic before age 10*P* value0--250 μg/l (*n* = 65)\>800 μg/l (*n* = 32)Female45 (69%)18 (56%)0.21Age in years48.9 ± 9.748.0 ± 6.20.62Height in centimeters161.1 ± 8.6162.3 ± 8.70.54Weight in kilograms72.2 ± 13.772.6 ± 15.60.90Obese (BMI ≥ 30 kg/m^2^)18 (28%)6 (19%)0.34Highest education completed Less than high school9 (14%)5 (16%)0.89 High school12 (19%)8 (25%)0.53 Technical school or incomplete university20 (31%)17 (53%)0.05 Graduated from university21 (32%)2 (6%)0.003 Data missing3 (5%)0 (0%)0.22Occupational vapors, dust, gas, or fumes^a^27 (42%)5 (16%)0.01Indoor air pollution reported^b^ Ever13 (20%)3 (9%)0.18 Before age ten9 (14%)3 (9%)0.53 Wood, charcoal, or kerosene in childhood home41 (63%)12 (38%)0.01Secondhand smoke exposure^c^ Ever35 (54%)16 (50%)0.60 Currently13 (20%)3 (9%)0.15 Before age ten11 (17%)12 (38%)0.02Smoking Ever40 (62%)24 (75%)0.19 Currently21 (32%)11 (34%)0.84 Age started20.2 ± 5.217.6 ± 3.70.04 Cigarettes per day ever^d,e^3.4 ± 5.44.2 ± 5.10.47 Pack-years^e^4.1 ± 8.14.9 ± 7.00.65Respiratory illness diagnosed ever Any^f^8 (12%)1 (3%)0.15 Chronic bronchitis0 (0%)1 (3%)0.16 Asthma5 (8%)0 (0%)0.11 Pulmonary tuberculosis4 (6%)0 (0%)0.15Lung function test quality Score^g^4.2 ± 1.13.8 ± 1.20.05 Reproducible results^h^60 (92%)28 (88%)0.45*BMI* body mass index^a^Reported for jobs held ≥6 months^b^Reported "irritating or visible smoke, vapors, gases, or dust regularly in same room"^c^Reported someone smoking regularly in same room^d^Average per day during period of regular smoking^e^Never smokers counted as zeroes^f^One subject reported both asthma and tuberculosis^g^Rated by EasyOne spirometer from 0 (no acceptable tests) to 5 (≥3 acceptable tests and difference between highest 2 forced expiratory volume in 1 s (FEV~1~) and forced vital capacity (FVC) values ≤150 ml)^h^Difference between highest 2 FEV~1~ and FVC values ≤200 ml

Results {#Sec9}
=======

As expected, participants reported nearly exclusive use of municipal sources in this desert region. Of the 32 subjects exposed to \>800 μg/l arsenic in drinking water before age 10, half were exposed in utero*.* The rest were either born before the peak exposure period began, or moved into the area after they were born. Of the 65 "unexposed" subjects, 20 drank water with 50--250 μg/l arsenic before age 10. No subject's highest drinking water arsenic concentration was between 250 and 800 μg/l.

Table [1](#Tab1){ref-type="table"} shows demographic and descriptive characteristics of participants. Subjects exposed to \>800 μg/l arsenic in drinking water before age 10 were more likely to have ever smoked regularly (75 vs. 62% of subjects without high early-life exposure), averaged more cigarettes per day (4.2 vs. 3.4), and started smoking earlier (17.6 vs. 20.2 years old). Additionally, more exposed subjects reported childhood secondhand smoke (38 vs. 17%) and fewer of them graduated university (6 vs. 32%). On the other hand, they reported less secondhand smoke currently (9 vs. 20% of unexposed), less occupational exposure to vapors, dusts, gases or fumes (16 vs. 42%), and less wood, charcoal, and kerosene fuel exposure before age 10 (38 vs. 63%). Adjusting for these and other potential confounders had little impact on associations between arsenic and lung function (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}). No subjects reported a past diagnosis of lung or any other type of cancer.Table 2Lung function residuals (observed minus predicted) and percent of age-, sex-, and height-predicted values (mean ± SD)All subjectsPeak arsenic before age 10CrudeAdjusted^a^0--250 μg/l (*n* = 65)\>800 μg/l (*n* = 32)Diff.*P* valueDiff.*P* valuePercent of predicted FEV~1~96.0 ± 13.988.1 ± 18.3−7.90.01−8.00.05Percent of predicted FVC101.9 ± 15.194.7 ± 15.3−7.20.02−7.90.05FEV~1~ residual (ml)−127 ± 417−375 ± 611−2480.01−2440.06FVC residual (ml)55 ± 532−226 ± 614−2800.01−3100.04*Never smokers*(*n* = 25)(*n* = 8)Percent of predicted FEV~1~97.7 ± 14.390.7 ± 15.1−7.00.12−16.90.02Percent of predicted FVC104.0 ± 17.293.3 ± 13.1−10.70.06−19.70.03FEV~1~ residual (ml)−77 ± 406−257 ± 414−1800.14−4960.02FVC residual (ml)129 ± 603−229 ± 427−3590.07−7160.03*Ever smokers*(*n* = 40)(*n* = 24)Percent of predicted FEV~1~95.0 ± 13.787.3 ± 19.5−7.70.03−4.70.22Percent of predicted FVC100.6 ± 13.795.2 ± 16.2−5.40.08−3.70.25FEV~1~ residual (ml)−158 ± 425−414 ± 667−2560.03−1560.22FVC residual (ml)8 ± 484−225 ± 672−2330.06−1800.20*Women*(*n* = 45)(*n* = 18)Percent of predicted FEV~1~94.6 ± 12.191.8 ± 15.8−2.80.22−1.70.37Percent of predicted FVC100.9 ± 14.998.7 ± 14.8−2.20.30−1.60.39FEV~1~ residual (ml)−153 ± 321−210 ± 412−560.28−170.45FVC residual (ml)11 ± 480−35 ± 472−460.37−270.44*Men*(*n* = 20)(*n* = 14)Percent of predicted FEV~1~99.3 ± 17.283.5 ± 20.7−15.80.01−14.20.12Percent of predicted FVC104.2 ± 15.689.6 ± 15.0−14.60.005−15.80.06FEV~1~ residual (ml)−66 ± 584−587 ± 762−5210.02−4400.15FVC residual (ml)153 ± 636−472 ± 700−6240.005−6730.07*Diff.* difference, *FEV*~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity^a^Adjusted for smoking, childhood secondhand smoke, wood, charcoal, or kerosene fuel use in childhood home, occupational air pollution, and educationTable 3Exposure response between early-life arsenic and lung function residuals (observed minus predicted) and percent of age-, sex-, and height-predicted values (mean ± SD)Peak arsenic before age 10\<50 μg/l (*n* = 45)50--250 μg/l (*n* = 20)\>800 μg/l (*n* = 32)Percent predicted FEV~1~98.2 ± 14.691.2 ± 11.088.1 ± 18.3Percent predicted FVC103.6 ± 16.798.2 ± 10.094.7 ± 15.3FEV~1~ residual (ml)−63 ± 443−270 ± 314−375 ± 611FVC residual (ml)103 ± 584−54 ± 380−226 ± 61450--250 compared to \<50 μg/l\>800 compared to \<50 μg/l*P* trend^b^CrudeAdjusted^a^CrudeAdjusted^a^CrudeAdjusted^a^Diff.*P* valueDiff.*P* valueDiff.*P* valueDiff.*P* valuePercent predicted FEV~1~−7.00.03−4.60.18−10.00.005−11.50.040.0050.03Percent predicted FVC−5.30.10−2.70.32−8.80.01−12.20.040.0080.03FEV~1~ residual (ml)−2080.03−1520.16−3120.006−3350.060.0050.03FVC residual (ml)−1570.14−520.40−3290.01−4290.040.0060.02*Diff.* difference, *FEV*~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity^a^Adjusted for smoking, childhood secondhand smoke, wood, charcoal, or kerosene fuel use in childhood home, occupational air pollution, and education^b^Highest known arsenic concentration before age 10 was entered as a continuous variable in linear modelsTable 4Prevalence odds ratios (PORs) and 95% confidence intervals (CIs) for respiratory symptomsPeak arsenic before age 10CrudeAdjusted^a^0--250 μg/l (*n* = 65)\> 800μg/l (*n* = 32)POR95% CI*P* valuePOR95% CI*P* valueChronic cough7 (11%)5 (16%)1.530.45--5.280.261.300.22--7.800.39Chronic phlegm5 (7%)2 (6%)0.800.15--4.370.380.930.10--9.010.48Chronic bronchitis2 (3%)1 (3%)1.020.09--11.60.49N/AN/AN/ATrouble breathing Rarely16 (25%)4 (13%)0.440.13--1.440.081.200.25--5.730.41 Often2 (3%)2 (6%)2.100.28--15.60.231.010.06--17.20.49Breathlessness walking Fast/uphill15 (23%)13 (41%)2.280.92--5.670.042.530.68--9.450.08 At group pace9 (14%)12 (38%)3.731.37--10.20.0045.941.36--26.00.009 At own pace7 (11%)10 (31%)3.771.27--11.10.0063.890.90--16.80.03Any respiratory symptom20 (31%)14 (44%)1.750.73--4.200.112.630.78--8.920.06*N/A* not available (adjustment variables missing for 1 "yes" respondent)^a^Adjusted for age, sex, smoking, childhood secondhand smoke, wood, charcoal, or kerosene fuel use in childhood home, occupational air pollution, and education

Table [2](#Tab2){ref-type="table"} shows lung function mean residuals (observed minus predicted) and percent of age-, sex-, and height-predicted values. High early-life arsenic exposure was associated with a 244-ml decrease in FEV~1~ (*P* = 0.06) and a 310-ml decrease in FVC (*P* = 0.04). In terms of percent of predicted values, this was equivalent to 8.0% lower FEV~1~ and 7.9% lower FVC (*P* = 0.05 for both). When analyses were restricted to the 33 subjects who reported never smoking regularly, effect estimates remained high but changed dramatically with adjustment (16.9 and 19.7% decreases in FEV~1~ and FVC, respectively; *P* \< 0.05 for both), suggesting unstable results due to the small number of subjects.

In analyses confined to concurrently assessed Antofagasta residents (*n* = 45), subjects who had either lived elsewhere or were older than 10 during the high exposure period served as the "unexposed" reference (*n* = 12). Effect estimates were similar, but the smaller sample size reduced statistical power (8.4 and 7.1% decreases in FEV~1~ and FVC (*P* = 0.10 for both)). Results were also similar when different age and arsenic concentration cut-offs were used to define early-life exposure. For example, with early-life exposure defined as \>200 μg/l arsenic before age 18, adjusted differences in FEV~1~ and FVC between exposed (*n* = 45) and unexposed (*n* = 52) were 9.5% (*P* = 0.02) and 11.7% (*P* = 0.006) (not shown in tables). Lung function deficits were similar (within 2% predicted) in analyses excluding the 9 participants without reproducible spirometry or the participants with the worst and best lung function (i.e., possible outliers).

Table [3](#Tab3){ref-type="table"} shows exposure--response relationships between peak arsenic concentration before age 10 and FEV~1~ and FVC, respectively (*P* trend = 0.03 for both). Participants were also stratified into 3 groups based on highest early-life arsenic concentration: \<50, 50--250, and \>800 μg/l. Subjects exposed to 50--250 μg/l and \>800 μg/l had 4.6% (*P* = 0.18) and 11.5% (*P* = 0.04) lower FEV~1~, respectively, than those exposed to \<50 μg/l. A similar pattern was seen for FVC. Effect estimates were similar when 8 subjects exposed to \>800 μg/l only after age 10 were put in the intermediate group or excluded entirely.

Table [4](#Tab4){ref-type="table"} shows prevalence of respiratory symptoms. Thirty-eight percent of exposed subjects reported breathlessness walking at a group pace compared to 14% of unexposed (POR = 5.94, 95% confidence interval (CI) 1.36--26.02). The POR for reporting *any* breathlessness was 2.53 (95% CI 0.68--9.45). There was little evidence of associations with chronic cough, phlegm, chronic bronchitis, or "trouble breathing," although few subjects reported these symptoms.

Discussion {#Sec10}
==========

The decreases in FEV~1~ and FVC and the PORs above 1.0 for breathlessness identified in this study suggest that early-life exposure to arsenic in drinking water affects lung function, and these effects remain many years after cessation of high exposure. Assuming each pack-year smoked is associated with a 7.4-ml decrease in FEV~1~ (Dockery et al. [@CR13]), the decrease in lung function we observed was similar in magnitude to that of 45 pack-years. To our knowledge, this is the first time a drinking water contaminant has been linked to lung function and respiratory symptoms 4 decades after peak exposure.

The exact mechanisms by which arsenic causes lung disease are unknown, and further research may be needed in this area. However, the biological plausibility that ingested arsenic can cause toxicity to the lungs is supported by a variety of studies. In rabbits, the species most similar to humans in terms of arsenic metabolism (NRC [@CR38]), arsenic has been shown to accumulate in the lung more than other organs except the liver and kidney, which are the primary sites of metabolism and excretion (Bertolero et al. [@CR3]; Marafante et al. [@CR33]). Other animal studies show that the primary metabolite of arsenic, dimethylarsinic acid (DMA), is retained longer in the lungs than in other tissues (Kenyon et al. [@CR29]; Vahter et al. [@CR54]). In humans, ingested arsenic is an established cause of lung cancer (IARC [@CR27]), and several studies have linked it to non-malignant respiratory effects including respiratory symptoms, pulmonary function, and a 10-fold increase in radiographically confirmed bronchiectasis (De et al. [@CR12]; Guha Mazumder et al. [@CR19], [@CR20]; Guo et al. [@CR21]; Milton and Rahman [@CR35]; Parvez et al. [@CR40]; Smith et al. [@CR49]; von Ehrenstein et al. [@CR55]). In fact, increases in human lung cancer risk are similar whether arsenic is ingested or inhaled (Smith et al. [@CR50]). This body of research provides evidence that the human lung is particularly susceptible to arsenic in drinking water.

Environmental exposures may be particularly harmful in early life because of rapid organogenesis and differences in children's water intake, metabolism, and detoxification (Landrigan et al. [@CR30]). Arsenic is known to cross the placenta and reach the fetus, and total arsenic levels in umbilical cord blood and maternal blood are similar (Concha et al. [@CR10]; Hall et al. [@CR22]; Vahter [@CR53]). Several studies have shown that metabolism of arsenic to its less toxic metabolite, DMA, is increased in pregnant women (Vahter [@CR53]). However, a recent study of mother--infant pairs in Bangladesh found that less than half of total arsenic in cord blood was DMA (Hall et al. [@CR22]). Other data suggest that arsenic metabolism may differ between children and adults, but these findings are not entirely consistent (Hall et al. [@CR23]). In a study in a highly exposed region of Argentina, children could not metabolize ingested inorganic arsenic to DMA as well as adults (Concha et al. [@CR9]). In utero arsenic exposures have been linked to reproductive outcomes including stillbirth (Hopenhayn-Rich et al. [@CR26]; Vahter [@CR52], [@CR53]; von Ehrenstein et al. [@CR56]) and, in male infants, smaller thymus size and acute respiratory illnesses (Raqib et al. [@CR46]). In mice, in utero drinking water arsenic exposure caused irreversible changes in airway reactivity to methacholine, altered gene and protein expression (Lantz et al. [@CR31]) and, at concentrations ≥42,500 ug/l, tumors in the lungs of offspring but not dams (Waalkes et al. [@CR57]). An ecologic study comparing the arsenic-exposed city of Antofagasta to other regions of Chile found that those exposed in early life had higher death rates from lung cancer (standardized mortality ratio (SMR) = 6.1, 95% CI 3.5--9.9), bronchiectasis (SMR = 46.2, 95% CI 21.1--87.7), and other COPD (SMR = 7.6, 95% CI 3.1--15.6) in adulthood (Smith et al. [@CR49]). These studies all support our results linking early-life arsenic ingestion to long-term respiratory effects.

Our results are consistent with the 2 previously published studies of ingested arsenic and lung function in people with probable adult exposures. In a study involving 31 subjects in Bangladesh, urinary arsenic concentration (indicative of current exposure) was inversely associated with percent predicted FEV~1~ and FVC (Parvez et al. [@CR40]). In 287 subjects from West Bengal, India, men with arsenic-caused skin lesions had 256 and 288 ml lower FEV~1~ and FVC, respectively, than those without skin lesions or known high arsenic exposures (von Ehrenstein et al. [@CR55]). The FEV~1~ deficits were much smaller in women (64 ml). We also found much smaller effects in women (17-ml FEV~1~ reduction versus 440 ml for men). Other studies have reported greater arsenic-associated health effects in men (Marshall et al. [@CR34]; Rahman et al. [@CR45]), perhaps due to sex-related differences in arsenic metabolism, water intake, occupational and other exposures (Hertz-Picciotto et al. [@CR25]; Lindberg et al. [@CR32]; Vahter [@CR53]). The greater effects observed in men in this study were not likely due to interactions with smoking since larger arsenic-associated lung function deficits were seen in never smokers, yet men smoked more than women in terms of the proportion of ever smokers (71% vs. 63%), pack-years (5.2 vs. 4.0), and cigarettes per day (4.2 vs. 3.4).

Strengths of our study include the accuracy of data on past arsenic exposure. In other places with widespread exposure, the abundance of private wells and other water sources, coupled with a lack of historical arsenic records, makes studies of long-term health effects much more difficult. By contrast, northern Chile has limited water sources and has arsenic records dating back more than 50 years, providing a unique opportunity to study the long-term impacts of exposure. The main limitation of this study is the convenience method of participant recruitment, raising concerns about inference and interpretation of results. Although the problem of arsenic in drinking water in northern Chile has been publicized, most information has been on cancer. Our experience is that very few people in the study cities know about the possible role of arsenic in non-malignant respiratory disease. This suggests that people with respiratory problems in Antofagasta (the exposed city) would not be more likely to participate than people with respiratory problems in Arica (the unexposed city), and differential selection is unlikely to account for the effects we identified. A second weakness of this study is that most exposed and unexposed subjects were not assessed concurrently. However, effect estimates remained similar in analyses confined to those who were.

Confounding due to smoking is unlikely to account for the effects identified in this study for 2 reasons. First, entering smoking information into multivariate models had little impact on the association between arsenic and lung function. Second, to explain the observed 8--12% decrease in FEV~1~, virtually all of the arsenic-exposed subjects would have to have smoked, while all unexposed would have to have been never smokers. In actuality, the 2 groups had similar smoking histories, and these Chilean smokers consumed fewer cigarettes per day than their U.S. counterparts (CDC [@CR7]). Although arsenic-exposed subjects had slightly less reproducibility of spirometry, less education, and more childhood secondhand smoke exposure, none of these variables were associated with decreased lung function in this study, and adjusting for them had little effect on results. The arsenic-exposed and arsenic-unexposed cities (Antofagasta and Arica) have historically had similar air pollution, industry (e.g., no large coal-fired power plant nearby), traffic patterns (e.g., 1 major highway), geography (coastal desert), sociodemographics, and dietary patterns (INE [@CR28]). Particulate matter of mass median aerodynamic diameter ≤10 μm (PM~10~) measurements, available for the past 10 years, are similar both at city centers and across neighborhoods of Antofagasta (mean 40.4, range 29.7--51.9 μg/m^3^) and Arica (mean 40.9, range 32.5--48.6 μg/m^3^). Nitrogen dioxide (NO~2~) levels are low in both cities, with annual averages around 8--12 μg/m^3^ (CENMA [@CR8]; SETEC [@CR1]). Although some arsenic exposures in this area also occur through air and food, these are minor compared to drinking water (Ferreccio and Sancha [@CR15]). Except for the nearly 100-fold contrast in past arsenic exposure, the 2 cities appear similar in all covariates related to lung function. Although confounding cannot be completely ruled out, it seems unlikely that some unknown confounder could cause the lung function decrements observed in subjects with high early-life arsenic exposures, similar in magnitude to decades of heavy smoking.

Federal and state regulations in the United States mandate protection of susceptible subgroups such as pregnant women and children. Without relevant studies, however, the U.S. Environmental Protection Agency has been unable to incorporate data on the long-term health effects of early-life exposures into any of its drinking water standards (Landrigan et al. [@CR30]). A lack of epidemiologic data is particularly problematic for addressing environmental exposures such as arsenic, for which there are major differences between humans and laboratory animals in metabolism, co-exposures, and potency (NRC [@CR39]). Several human studies have assessed the impacts of early-life environmental exposures, but these have typically involved short follow-up periods, small numbers of study subjects, or small effect sizes. For example, dioxins in breast milk were linked to a lower FEV~1~/FVC ratio in Danish children (mean age 8.2 years), but the sample size was only 29 (ten Tusscher et al. [@CR51]). In a meta-analysis involving 53,879 children, parental smoking was linked to respiratory symptoms, but relative risks were generally low (around 1.15) (Pattenden et al. [@CR41]). In a subsample of 22,712 of these children with valid lung function data, maternal smoking during pregnancy was linked to a 1% decrease in FEV~1~ and essentially no change in FVC (Moshammer et al. [@CR36]). In a longitudinal study on outdoor air pollution in southern California, the mean difference in FEV~1~ growth from age 10 to 18 between the most exposed city (PM~10~ = 68 μg/m^3^) and the least exposed city (PM~10~ = 17 μg/m^3^) was 82 ml. Similar effects were seen for PM~2.5~, NO~2~, and acid vapor (Gauderman et al. [@CR18]). In the current study, we observed 4-fold larger FEV~1~ decrements (335 ml) nearly 40 years after high arsenic exposures ended.

Conclusions {#Sec11}
===========

This study provides the first evidence that in utero and childhood exposure to arsenic in drinking water is associated with long-term lung function deficits and shortness of breath in humans. The magnitude of the decrease in both FEV~1~ and FVC suggests that early-life arsenic exposure could have effects similar to smoking throughout adulthood and greater effects than secondhand smoke or air pollution. Nonetheless, certain potential biases---especially those related to non-random selection of subjects---were not controlled for and cannot be excluded. These results should be confirmed in a larger study with participants who are representative of the source population. A larger study could also investigate the effects of lower exposures as well as effect modification and confounding by factors such as diet, occupational exposures, smoking, and gender. The public health importance lies in the enormous morbidity and mortality associated with respiratory effects of this magnitude, the millions of children with high exposures worldwide, and the need to incorporate data on early-life susceptibility into environmental policy.
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